Clinical Oncology/Epidemiology |
Clinical Oncology/Epidemiology
Filters
-
Article Type
- All (1819)
- Clinical Oncology/Epidemiology (1819)
-
Year
-
-
Clinical Oncology/Epidemiology |
Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer
- H Gabra
- , DA Cameron
- , LE Lee
- , J Mackay
- & RCF Leonard
-
Clinical Oncology/Epidemiology |
Prolonged intraperitoneal infusion of 5-fluorouracil using a novel carrier solution
- DJ Kerr
- , AM Young
- , JP Neoptolemos
- , M Sherman
- , P Van-Geene
- , A Stanley
- , D Ferry
- , JW Dobbie
- , B Vincke
- , J Gilbert
- , D el Eini
- , N Dombros
- & G Fountzilas
-
Clinical Oncology/Epidemiology |
High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer--phase I/II study
- DA Cameron
- , J Craig
- , H Gabra
- , L Lee
- , J MacKay
- , AC Parker
- , RCF Leonard
- , E Anderson
- , T Anderson
- , U Chetty
- , M Dixon
- , A Hawkins
- , W Jack
- , I Kunkler
- , R Leonard
- , L Matheson
- & W Miller
-
Clinical Oncology/Epidemiology |
Pain and other symptoms during the first year after radical and conservative surgery for breast cancer
- T Tasmuth
- , K von Smitten
- & E Kalso
-
Clinical Oncology/Epidemiology |
Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity
- C Bokemeyer
- , LM Fels
- , T Dunn
- , W Voigt
- , J Gaedeke
- , H-J Schmoll
- , H Stolte
- & H Lentzen
-
Clinical Oncology/Epidemiology |
High risk of lymphomas in children of Asian origin: ethnicity or confounding by socioeconomic status?
- C Varghese
- , JH Barrett
- , C Johnston
- , M Shires
- , L Rider
- & D Forman
-
Clinical Oncology/Epidemiology |
Trends in eye cancer mortality among adults in the USA and England and Wales
- AJE Foss
- & PJ Dolin
-
Clinical Oncology/Epidemiology |
Cancer mortality in French Polynesia between 1984 and 1992
- F de Vathaire
- & B Le Vu
-
Clinical Oncology/Epidemiology |
Allelic loss at chromosome 13q12-q13 is associated with poor prognosis in familial and sporadic breast cancer
- J van den Berg
- , O Johannsson
- , S Håkansson
- , H Olsson
- & A Borg
-
Clinical Oncology/Epidemiology |
Analysis of polypeptide expression in benign and malignant human breast lesions: down-regulation of cytokeratins
- B Franzén
- , S Linder
- , AA Alaiya
- , E Eriksson
- , K Uruy
- , T Hirano
- , K Okuzawa
- & G Auer
-
Clinical Oncology/Epidemiology |
High dose rate brachytherapy before external beam irradiation in inoperable oesophageal cancer
- BG Taal
- , BMP Aleman
- , CCE Koning
- & H Boot
-
Clinical Oncology/Epidemiology |
Loss of interleukin 4 receptor-associated molecule gp200-MR6 in human breast cancer: prognostic significance
- L Kaklamanis
- , MI Koukourakis
- , R Leek
- , A Giatromanolaki
- , M Ritter
- , R Whitehouse
- , KC Gatter
- & AL Harris
-
Clinical Oncology/Epidemiology |
A comparison of axillary node status between cancers detected at the prevalence and first incidence breast screening rounds
- PA Holland
- , J Walls
- , CR Boggis
- , F Knox
- , AD Baildam
- & NJ Bundred
-
Clinical Oncology/Epidemiology |
A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients
- P Lissoni
- , F Paolorossi
- , G Tancini
- , A Ardizzoia
- , S Barni
- , F Brivio
- , GJM Maestroni
- & M Chilelli
-
Clinical Oncology/Epidemiology |
Management preferences in stage I non-seminomatous germ cell tumours of the testis: an investigation among patients, controls and oncologists
- MH Cullen
- , LJ Billingham
- , J Cook
- & CM Woodroffe
-
Clinical Oncology/Epidemiology |
Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer
- AA Melcher
- , D Mort
- & TS Maughan
-
Clinical Oncology/Epidemiology |
Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer
- GJS Rustin
- , TG Quinnell
- , J Johnson
- , H Clarke
- , AE Nelstrop
- & W Bollag
-
Clinical Oncology/Epidemiology |
Epidemiology of Kaposi's sarcoma in the Nordic countries before the AIDS epidemic
- H Hjalgrim
- , M Melbye
- , E Pukkala
- , F Langmark
- , M Frisch
- , M Dictor
- & A Ekbom
-
Clinical Oncology/Epidemiology |
Case-control study of risk factors for prostate cancer
- M Ilić
- , H Vlajinac
- & J Marinković
-
Clinical Oncology/Epidemiology |
An increased NM23H1 copy number may be a poor prognostic factor independent of LOH on 1p in neuroblastomas
- O Takeda
- , M Handa
- , T Uehara
- , N Maseki
- , A Sakashita
- , M Sakurai
- , N Kanda
- , Y Arai
- & Y Kaneko
-
Clinical Oncology/Epidemiology |
Keratin 19 mRNA measurement to detect micrometastases in lymph nodes in breast cancer patients
- A Schoenfeld
- , Y Luqmani
- , HD Sinnett
- , S Shousha
- & RC Coombes
-
Clinical Oncology/Epidemiology |
A clinicopathological study of asymptomatic gastric cancer
- A Matsukuma
- , M Furusawa
- , H Tomoda
- & Y Seo
-
Clinical Oncology/Epidemiology |
Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy
- SD Fosså
- , C Sternberg
- , HI Scher
- , CH Theodore
- , B Mead
- , D Dearnaley
- , JT Roberts
- & E Skovlund
-
Clinical Oncology/Epidemiology |
A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily
- P Savage
- , V Horton
- , J Moore
- , M Owens
- , P Witt
- & ME Gore
-
Clinical Oncology/Epidemiology |
Initial prognostic factors in small-cell lung cancer patients predicting quality of life during chemotherapy
- J Bernhard
- , C Hürny
- , M Bacchi
- , RA Joss
- , F Cavalli
- , H-J Senn
- , S Leyvraz
- , R Stahel
- , C Ludwig
- & P Alberto
-
Clinical Oncology/Epidemiology |
What do cancer patients mean when they complain of concentration and memory problems?
- A Cull
- , C Hay
- , SB Love
- , M Mackie
- , E Smets
- & M Stewart
-
Clinical Oncology/Epidemiology |
Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients
- DM Barnes
- , WH Harris
- , P Smith
- , RR Millis
- & RD Rubens
-
Clinical Oncology/Epidemiology |
Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi
- G MacGrogan
- , L Mauriac
- , M Durand
- , F Bonichon
- , M Trojani
- , I de Mascarel
- & JM Coindre
-
Clinical Oncology/Epidemiology |
Prospective evaluation of prognostic factors in operable breast cancer
- RA Hawkins
- , AL Tesdale
- , ME Killen
- , WJL Jack
- , U Chetty
- , JM Dixon
- , MJ Hulme
- , RJ Prescott
- , MA McIntyre
- & WR Miller
-
Clinical Oncology/Epidemiology |
Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria
- EW Steyerberg
- , HJ Keizer
- , SD Fosså
- , DT Sleijfer
- , DF Bajorin
- , JP Donohue
- & JDF Habbema
-
Clinical Oncology/Epidemiology |
Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor
- GV Kornek
- , K Haider
- , W Kwasny
- , M Hejna
- , M Raderer
- , S Meghdadi
- , D Burger
- , B Schneeweiss
- , D Depisch
- & W Scheithauer
-
Clinical Oncology/Epidemiology |
Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer
- J Geisler
- , N King
- , M Dowsett
- , L Ottestad
- , S Lundgren
- , P Walton
- , PO Kormeset
- & PE Lønning
-
Clinical Oncology/Epidemiology |
Emotional support for cancer patients: what do patients really want?
- ML Slevin
- , SE Nichols
- , SM Downer
- , P Wilson
- , TA Lister
- , S Arnott
- , J Maher
- , RL Souhami
- , JS Tobias
- , AH Goldstone
- & M Cody
-
Clinical Oncology/Epidemiology |
Plasma nitrate plus nitrite changes during continuous intravenous infusion interleukin 2
- G Citterio
- , F Pellegatta
- , GD Lucca
- , G Fragasso
- , U Scaglietti
- , D Pini
- , C Fortis
- , M Tresoldi
- & C Rugarli
-
Clinical Oncology/Epidemiology |
Non-melanoma skin cancer and solar keratoses II analytical results of the South Wales Skin Cancer Study
- I Harvey
- , S Frankel
- , R Marks
- , D Shalom
- & M Nolan-Farrell
-
Clinical Oncology/Epidemiology |
Impact of tumour burden on chemotherapy-induced nausea and vomiting
- TJ Hursti
- , E Åvall-Lundqvist
- , S Börjeson
- , M Fredrikson
- , CJ Fürst
- , G Steineck
- & C Peterson
-
Clinical Oncology/Epidemiology |
Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: increased efficacy and reduced toxicity when given subcutaneously
- AH Honkoop
- , K Hoekman
- , J Wagstaff
- , CJ van Groeningen
- , JB Vermorken
- , E Boven
- & HM Pinedo
-
Clinical Oncology/Epidemiology |
Multistage designs for phase II clinical trials: statistical issues in cancer research
- A Kramar
- , D Potvin
- & C Hill
-
Clinical Oncology/Epidemiology |
Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxorubicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer
- A Ardizzoni
- , MC Pennucci
- , M Danova
- , C Viscoli
- , GL Mariani
- , G Giorgi
- , M Venturini
- , C Mereu
- , T Scolaro
- & R Rosso
-
Clinical Oncology/Epidemiology |
Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience
- A Gerl
- , C Clemm
- , N Schmeller
- , R Hartenstein
- , R Lamerz
- & W Wilmanns
-
Clinical Oncology/Epidemiology |
A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer
- DW Miles
- , KE Towlson
- , R Graham
- , M Reddish
- , BM Longenecker
- , J Taylor-Papadimitriou
- & RD Rubens
-
Clinical Oncology/Epidemiology |
Non-melanoma skin cancer and solar keratoses. I. Methods and descriptive results of the South Wales Skin Cancer Study
- I Harvey
- , S Frankel
- , R Marks
- , D Shalom
- & M Nolan-Farrell
-
Clinical Oncology/Epidemiology |
A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma
- FY Ahmed
- , GA Leonard
- , R A'Hern
- , AE Taylor
- , A Lorentzos
- , H Atkinson
- , J Moore
- , MC Nicolson
- , PG Riches
- & ME Gore
-
Clinical Oncology/Epidemiology |
Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3
- R Molina
- , J Jo
- , G Zanón
- , X Filella
- , B Farrus
- , M Muñoz
- , ML Latre
- , J Pahisa
- , M Velasco
- , P Fernandez
- , J Estapé
- & AM Ballesta
-
Clinical Oncology/Epidemiology |
Cigarette smoking and urinary oestrogen excretion in premenopausal and post-menopausal women
- TJA Key
- , MC Pike
- , JB Brown
- , C Hermon
- , DS Allen
- & DY Wang
-
Clinical Oncology/Epidemiology |
5-Hydroxyindoleacetic acid (5-HIAA) and cortisol excretion as predictors of chemotherapy-induced emesis
- A du Bois
- , W Vach
- , U Wechsel
- , R Holy
- & W Schaefer
-
Clinical Oncology/Epidemiology |
Incidence of invasive cancers following carcinoma in situ of the cervix
- F Levi
- , L Randimbison
- , C La Vecchia
- & S Franceschi
-
Clinical Oncology/Epidemiology |
Birth characteristics and risk of Wilms' tumour: a nationwide prospective study in Norway
- JM Heuch
- , I Heuch
- & G Kvåle
-
Clinical Oncology/Epidemiology |
pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients
- I Soubeyran
- , N Quénel
- , J-M Coindre
- , F Bonichon
- , M Durand
- , J Wafflart
- & L Mauriac
